H
048410
vs
K
KOSPI 200
Over the past 12 months, Hyundai Bioscience Co Ltd has underperformed KOSPI 200, delivering a return of +11% compared to KOSPI 200's +150% growth.
Stocks Performance
048410 vs KOSPI 200
Performance Gap
048410 vs KOSPI 200
Performance By Year
048410 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Hyundai Bioscience Co Ltd
Glance View
Hyundai Bioscience is a South Korean biotechnology company that develops drug candidates and related medical products, with a strong focus on treatments for infectious diseases and other hard-to-treat conditions. Its business is built around researching new compounds, testing them through clinical development, and trying to turn them into approved medicines or licensed assets. The company makes money through drug sales where products are commercialized, and through licensing, research partnerships, and other development agreements tied to its drug pipeline. Its main customers are healthcare providers, distributors, and pharmaceutical partners that buy, use, or help develop its medicines and technologies. What makes the business different is that it is not a mass-market consumer health brand. It is a drug-development company, so most of its value comes from intellectual property, clinical progress, and regulatory approvals rather than from steady day-to-day product sales.
